[HTML][HTML] Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management

PS Rawat, A Jaiswal, A Khurana, JS Bhatti… - Biomedicine & …, 2021 - Elsevier
Doxorubicin (Dox) is a secondary metabolite of the mutated strain of Streptomyces peucetius
var. Caesius and belongs to the anthracyclines family. The anti-cancer activity of Dox is …

Mitochondrial determinants of doxorubicin-induced cardiomyopathy

KB Wallace, VA Sardão, PJ Oliveira - Circulation research, 2020 - Am Heart Assoc
Anthracycline-based chemotherapy can result in the development of a cumulative and
progressively developing cardiomyopathy. Doxorubicin is one of the most highly prescribed …

Mitochondrial pyruvate transport: a historical perspective and future research directions

KS McCommis, BN Finck - Biochemical journal, 2015 - portlandpress.com
Pyruvate is the end-product of glycolysis, a major substrate for oxidative metabolism, and a
branching point for glucose, lactate, fatty acid and amino acid synthesis. The mitochondrial …

Analysis of models of doxorubicin-induced cardiomyopathy in rats and mice. A modern view from the perspective of the pathophysiologist and the clinician

EY Podyacheva, EA Kushnareva, AA Karpov… - Frontiers in …, 2021 - frontiersin.org
Today the pharmacological possibilities of treating cancer are expanding and as a result, life
expectancy is increasing against the background of chemotherapy and supportive treatment …

[HTML][HTML] Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies

Y Octavia, CG Tocchetti, KL Gabrielson… - Journal of molecular and …, 2012 - Elsevier
The utility of anthracycline antineoplastic agents in the clinic is compromised by the risk of
cardiotoxicity. It has been calculated that approximately 10% of patients treated with …

Doxorubicin‐induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy

FS Carvalho, A Burgeiro, R Garcia… - Medicinal research …, 2014 - Wiley Online Library
Doxorubicin (DOX) is an anticancer anthracycline that presents a dose‐dependent and
cumulative cardiotoxicity as one of the most serious side effects. Several hypotheses have …

Updates in anthracycline-mediated cardiotoxicity

CG Nebigil, L Désaubry - Frontiers in Pharmacology, 2018 - frontiersin.org
Cardiotoxicity is one of the main adverse effects of chemotheraphy, affecting the completion
of cancer therapies and the short-and long-term quality of life. Anthracyclines are currently …

Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection

M Štěrba, O Popelová, A Vávrová… - Antioxidants & redox …, 2013 - liebertpub.com
Abstract Significance: Anthracyclines (doxorubicin, daunorubicin, or epirubicin) rank among
the most effective anticancer drugs, but their clinical usefulness is hampered by the risk of …

Mitochondrial dysfunction at the crossroad of cardiovascular diseases and cancer

C Rocca, T Soda, EM De Francesco, M Fiorillo… - Journal of Translational …, 2023 - Springer
A large body of evidence indicates the existence of a complex pathophysiological
relationship between cardiovascular diseases and cancer. Mitochondria are crucial …

Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance

HS Al-Malky, SE Al Harthi… - Journal of Oncology …, 2020 - journals.sagepub.com
Background Doxorubicin is one of the most commonly prescribed and time-tested anticancer
drugs. Although being considered as a first line drug in different types of cancers, the two …